Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor

TFPI (tissue factor pathway inhibitor) is an anticoagulant protein that prevents intravascular coagulation through inhibition of fXa (Factor Xa) and the TF (tissue factor)–fVIIa (Factor VIIa) complex. Localization of TFPI within caveolae enhances its anticoagulant activity. To define further how cav...

Full description

Bibliographic Details
Main Authors: Maroney, S., Ellery, Paul, Wood, J., Ferrel, J., Bonesho, C., Mast, A.
Format: Journal Article
Published: 2012
Online Access:http://hdl.handle.net/20.500.11937/38422
_version_ 1848755316478443520
author Maroney, S.
Ellery, Paul
Wood, J.
Ferrel, J.
Bonesho, C.
Mast, A.
author_facet Maroney, S.
Ellery, Paul
Wood, J.
Ferrel, J.
Bonesho, C.
Mast, A.
author_sort Maroney, S.
building Curtin Institutional Repository
collection Online Access
description TFPI (tissue factor pathway inhibitor) is an anticoagulant protein that prevents intravascular coagulation through inhibition of fXa (Factor Xa) and the TF (tissue factor)–fVIIa (Factor VIIa) complex. Localization of TFPI within caveolae enhances its anticoagulant activity. To define further how caveolae contribute to TFPI anticoagulant activity, CHO (Chinese-hamster ovary) cells were co-transfected with TF and membrane-associated TFPI targeted to either caveolae [TFPI–GPI (TFPI–glycosylphosphatidylinositol anchor chimaera)] or to bulk plasma membrane [TFPI–TM (TFPI–transmembrane anchor chimaera)]. Stable clones had equal expression of surface TF and TFPI. TX-114 cellular lysis confirmed localization of TFPI–GPI to detergent-insoluble membrane fractions, whereas TFPI–TM localized to the aqueous phase. TFPI–GPI and TFPI–TM were equally effective direct inhibitors of fXa in amidolytic assays. However, TFPI–GPI was a significantly better inhibitor of TF–fVIIa than TFPI–TM, as measured in both amidolytic and plasma-clotting assays. Disrupting caveolae by removing membrane cholesterol from EA.hy926 cells, which make TFPIα, CHO cells transfected with TFPIβ and HUVECs (human umbilical vein endothelial cells) did not affect their fXa inhibition, but significantly decreased their inhibition of TF–fVIIa. These studies confirm and quantify the enhanced anticoagulant activity of TFPI localized within caveolae, demonstrate that caveolae enhance the inhibitory activity of both TFPI isoforms and define the effect of caveolae as specifically enhancing the anti-TF activity of TFPI.
first_indexed 2025-11-14T08:54:22Z
format Journal Article
id curtin-20.500.11937-38422
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:54:22Z
publishDate 2012
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-384222023-02-22T06:24:17Z Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor Maroney, S. Ellery, Paul Wood, J. Ferrel, J. Bonesho, C. Mast, A. TFPI (tissue factor pathway inhibitor) is an anticoagulant protein that prevents intravascular coagulation through inhibition of fXa (Factor Xa) and the TF (tissue factor)–fVIIa (Factor VIIa) complex. Localization of TFPI within caveolae enhances its anticoagulant activity. To define further how caveolae contribute to TFPI anticoagulant activity, CHO (Chinese-hamster ovary) cells were co-transfected with TF and membrane-associated TFPI targeted to either caveolae [TFPI–GPI (TFPI–glycosylphosphatidylinositol anchor chimaera)] or to bulk plasma membrane [TFPI–TM (TFPI–transmembrane anchor chimaera)]. Stable clones had equal expression of surface TF and TFPI. TX-114 cellular lysis confirmed localization of TFPI–GPI to detergent-insoluble membrane fractions, whereas TFPI–TM localized to the aqueous phase. TFPI–GPI and TFPI–TM were equally effective direct inhibitors of fXa in amidolytic assays. However, TFPI–GPI was a significantly better inhibitor of TF–fVIIa than TFPI–TM, as measured in both amidolytic and plasma-clotting assays. Disrupting caveolae by removing membrane cholesterol from EA.hy926 cells, which make TFPIα, CHO cells transfected with TFPIβ and HUVECs (human umbilical vein endothelial cells) did not affect their fXa inhibition, but significantly decreased their inhibition of TF–fVIIa. These studies confirm and quantify the enhanced anticoagulant activity of TFPI localized within caveolae, demonstrate that caveolae enhance the inhibitory activity of both TFPI isoforms and define the effect of caveolae as specifically enhancing the anti-TF activity of TFPI. 2012 Journal Article http://hdl.handle.net/20.500.11937/38422 10.1042/BJ20111994 unknown
spellingShingle Maroney, S.
Ellery, Paul
Wood, J.
Ferrel, J.
Bonesho, C.
Mast, A.
Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor
title Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor
title_full Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor
title_fullStr Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor
title_full_unstemmed Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor
title_short Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor
title_sort caveolae optimize tissue factor-factor viia inhibitory activity of cell-surface-associated tissue factor pathway inhibitor
url http://hdl.handle.net/20.500.11937/38422